nsc-4347 and Osteoporosis

nsc-4347 has been researched along with Osteoporosis* in 3 studies

Reviews

2 review(s) available for nsc-4347 and Osteoporosis

ArticleYear
Effects of
    Endocrine, metabolic & immune disorders drug targets, 2023, Volume: 23, Issue:7

    Piper sarmentosum (PS) is a traditional herb used by Southeast Asian communities to treat various illnesses. Recent pharmacological studies have discovered that PS possesses antioxidant and anti-inflammatory activities. Since oxidative stress and inflammation are two important processes driving the pathogenesis of bone loss, PS may have potential therapeutic effects against osteoporosis.. This review systematically summarised the therapeutic effects of PS on preventing osteoporosis and promoting fracture healing.. A systematic literature search was performed in November 2021 using 4 electronic databases and the search string "Piper sarmentosum" AND (bone OR osteoporosis OR osteoblasts OR osteoclasts OR osteocytes).. Nine unique articles were identified from the literature. The efficacy of PS has been studied in animal models of osteoporosis induced by ovariectomy and glucocorticoids, as well as bone fracture models. PS prevented deterioration of bone histomorphometric indices, improved fracture healing and restored the biomechanical properties of healed bone in ovariectomised rats. PS also prevented osteoblast/osteocyte apoptosis, increased bone formation and mineralisation and subsequently improved trabecular bone microstructures and strength of rats with osteoporosis induced by glucocorticoids. Apart from its antioxidant and anti-inflammatory activity, PS also suppressed circulating and skeletal expression of corticosterone and skeletal expression of 11β hydroxysteroid dehydrogenase type 1 but increased the enzyme activity in the glucocorticoid osteoporosis model. This review also identified several research gaps about the skeletal effects of PS and suggested future studies to bridge these gaps.. PS may be of therapeutic benefit to bone health. However, further research is required to validate this claim.

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Bone Density; Female; Fracture Healing; Glucocorticoids; Osteoporosis; Piper; Plant Extracts; Rats

2023
Piper sarmentosum: a new hope for the treatment of osteoporosis.
    Current drug targets, 2013, Volume: 14, Issue:14

    Osteoporosis is a major global health problem. Osteoporosis is characterized by the loss of bone mass and strength which leads to an increased risk of fracture. Glucocorticoid treatment is the leading cause of secondary osteoporosis. Glucocorticoid action in bone depends upon the expression of 11beta-hydroxysteroid dehydrogenase type 1 enzyme (11β-HSD1). The oestrogen deficient state causes osteoporosis due to enhancement of osteoclastogenesis by oxidative stress which leads to increased bone resorption. Piper sarmentosum (Daun Kaduk) is commonly used in the local cuisine of South East Asia. It is also traditionally used to treat many diseases such as inflammation, dermatitis and joint pain. Studies have revealed antioxidant properties through its flavonoids compound naringenin which acts as a superoxide scavenger that may help in the endogenous antioxidant defence system to protect bone against osteoporosis. Recent studies found that Ps extract has the ability to inhibit the expression and activity of 11β-HSD1 in adipose tissue and bone which restored bone structure and strength. It also accelerates fracture healing in the oestrogen deficient state through its antioxidant properties. The cost of conventional treatment is high and together with the adverse effects it leads to noncompliance. Treatment modalities with herbal medicine, less side effects and is cheaper need to be explored.This review focused on the therapeutic effect of Ps extract on fracture healing in ovariectomized rats and its protective effects against glucocorticoid induced osteoporotic rats.

    Topics: Animals; Bone Resorption; Flavanones; Fracture Healing; Fractures, Bone; Glucocorticoids; Humans; Malaysia; Medicine, East Asian Traditional; Osteoporosis; Piper; Plant Extracts; Receptors, Estrogen

2013

Other Studies

1 other study(ies) available for nsc-4347 and Osteoporosis

ArticleYear
Piper sarmentosum prevents glucocorticoid-induced osteoporotic bone resorption by increasing 11β-hydroxysteroid dehydrogenase type 1 activity.
    La Clinica terapeutica, 2011, Volume: 162, Issue:4

    Osteoporosis is a proven complication of long-term glucocorticoid therapy. Concern on glucocorticoid induced osteoporosis has increased dramatically in recent years with the widespread use of synthetic glucocorticoids. Glucocorticoid action in bone depends upon the activity of 11βhydroxysteroid dehydrogenase type 1 enzyme (11βHSD1). This enzyme plays an important role in regulating corticosteroids by locally interconverting cortisone into active cortisol. This has been demonstrated in primary cultures of human, mouse or rat osteoblasts. Therefore, inhibition of this enzyme may reduce bone resorption markers. Piper sarmentosum (Ps) is a potent inhibitor of 11βHSD1 in liver and adipose tissue. In this study we determined the effect of Ps on 11βHSD1 activity in bones of glucocorticoid-induced osteoporotic rats.. Three-month old male Sprague-Dawley rats were adrenalectomised to remove the main source of circulating glucocorticoids. The animals were administered with dexamethasone 120 µg/kg body weight/day. Treatment with Ps 125 mg/kg body weight and glycirrhizic acid (GCA) 120 mg/kg body weight were given simultaneously.. The results showed that Ps extract reduced plasma corticosterone concentration (1.05+0.02 µg/ml) and induced 11βHSD1 dehydrogenase activity in bone (87.69+1.41%). Consequently, it also reduced the bone resorption marker, pyridinoline, in dexamethasone-treated adrenalectomised rats (2.07+0.62/L). Despite that, our data showed an inverse relationship between the plasma corticosterone level and the dehydrogenase activity of 11βHSD1 in the bone.. This suggests that 11βHSD1 acts as the local regulator of glucocorticoid and its activity in bone was not correlated to systemic corticosterone level.

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenalectomy; Animals; Biomarkers; Bone Resorption; Corticosterone; Dexamethasone; Drug Evaluation, Preclinical; Enzyme Induction; Femur; Glucocorticoids; Glycyrrhizic Acid; Male; Osteoblasts; Osteoclasts; Osteoporosis; Phytotherapy; Piper; Plant Extracts; Rats; Rats, Sprague-Dawley

2011